Tianjin Pharma Confirms Proceeds Management

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (SG:T14) has released an update.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has issued a report confirming the responsible management of net proceeds from their Placement, which after expenses netted approximately RMB 814,340,000 from the issuance of 29,564,356 A-shares. The Board reassures stakeholders of the accuracy and fairness of the financial information provided, in line with regulatory guidelines. This follows a series of prior announcements and circulars relating to the company’s financial activities and regulatory compliance.

For further insights into SG:T14 stock, check out TipRanks’ Stock Analysis page.